The High Q Foundation, Inc. is a private philanthropic foundation that was established in 2002 with the mission of bringing together academia, industry, governmental agencies, and other funding organizations in the search for Huntington disease (HD) treatments. The Foundation supports numerous projects related to HD, including basic research, a drug-discovery program, and clinical studies.
High Q supports directly research on target identification and validation, and biomarker development.
High Q's drug discovery program is conducted through CHDI, Inc., a not-for-profit organization pursuing a biotech strategy.
High Q supports HD clinical research through the Huntington Project.
For more information about High Q's HD research support, please contact:
MRSSI, Inc. was established in 2002 to provide administrative, management and grant-making services to non-profit organizations dedicated to researching HD.
September 22nd, 2006
PsychoGenics expands Huntington disease research collaboration with High Q Foundation and CHDI (pdf)
September 21st, 2006
Trophos SA and CHDI, Inc. extend partnership to develop promising compounds in models relevant to Huntington disease (pdf)
September 18th, 2006
CHDI selects Amphora Discovery's integrated discovery services in pursuit of Huntington disease cure (pdf)
August 10th, 2006
CHDI selects Evotec as strategic drug discovery partner in the search for Huntington disease treatments (pdf)
August 1st, 2006
CHDI and Edison enter collaborative agreement to develop analogs of CoQ10 (pdf)